Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 29, Issue 4, pp 516–528 | Cite as

Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician

  • S. Michael Gharacholou
  • Renato D. Lopes
  • Jeffrey B. Washam
  • L. Kristin Newby
  • Stefan K. James
  • John H. AlexanderEmail author
Article

Abstract

The use of anticoagulant and antiplatelet therapy during the management of acute coronary syndromes (ACS) has been associated with improvements in short- and long-term clinical outcomes, regardless of whether patients are managed conservatively or with acute coronary revascularization. Translating the existing evidence for selection of the most appropriate antithrombotic strategy has been summarized in available guideline recommendations. Given the breadth of antithrombotic recommendations across existing U.S. and European guidelines, synthesis of these recommendations for practicing clinicians who treat patients with ACS are increasingly desired. Providing a summary of the similarities across guidelines while noting the areas where divergence exists becomes an important facet in translating optimal antithrombotic management in ACS for the treating clinician. This review highlights the important aspects of clinical practice guidelines that practicing physicians should consider when selecting antithrombotic therapies to reduce ischemic risk while minimizing hemorrhagic risk across all ACS subtypes.

Keywords

Antithrombotic therapy Acute coronary syndromes Guidelines 

References

  1. 1.
    World Health Organization (2003) Prevention of recurrent heart attacks and strokes in low and middle income populations: evidence-based recommendations for policy makers and health professionals. WHO Press, GenevaGoogle Scholar
  2. 2.
    Libby P (2001) Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104:365–372PubMedGoogle Scholar
  3. 3.
    Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 50:e1–e157Google Scholar
  4. 4.
    Antman EM, Anbe DT, Armstrong PW et al (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 110:588–636Google Scholar
  5. 5.
    Cannon CP, Weintraub WS, Demopoulos LA et al (2001) Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344:1879–1887CrossRefPubMedGoogle Scholar
  6. 6.
    Skolnick AH, Alexander KP, Chen AY et al (2007) Characteristics, management, and outcomes of 5, 557 patients age > or = 90 years with acute coronary syndromes: results from the CRUSADE Initiative. J Am Coll Cardiol 49:1790–1797CrossRefPubMedGoogle Scholar
  7. 7.
    Mehta SR, Cannon CP, Fox KA et al (2005) Routine versus selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 293:2908–2917CrossRefPubMedGoogle Scholar
  8. 8.
    Alexander KP, Newby LK, Cannon CP et al (2007) Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 115:2549–2569CrossRefPubMedGoogle Scholar
  9. 9.
    Pfisterer M, Brunner-LaRocca HP, Buser PT et al (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48:2584–2591CrossRefPubMedGoogle Scholar
  10. 10.
    Douglas PS, Brennan JM, Anstrom KJ et al (2009) Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol 53:1629–1641CrossRefPubMedGoogle Scholar
  11. 11.
    Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015CrossRefPubMedGoogle Scholar
  12. 12.
    James S, Stenestrand U, Lindbäck J et al (2009) Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 360:1933–1945CrossRefPubMedGoogle Scholar
  13. 13.
    Alexander KP, Chen AY, Roe MT et al (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294:3108–3116CrossRefPubMedGoogle Scholar
  14. 14.
    Subherwal S, Bach RG, Chen AY et al (2009) Baseline risk of major bleeding in non-ST-segment elevation myocardial infarction: the CRUSADE (can rapid risk stratification of unstable angina patients suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score. Circulation 119:1873–1882CrossRefPubMedGoogle Scholar
  15. 15.
    Chase AJ, Fretz EB, Warburton WP et al (2008) Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L (mortality benefit of reduced transfusion after percutaneous coronary intervention via the arm or leg) study. Heart 94:1019–1025CrossRefPubMedGoogle Scholar
  16. 16.
    Roy P, Bonello L, Torguson R et al (2008) Impact of “nuisance” bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 102:1614–1617CrossRefPubMedGoogle Scholar
  17. 17.
    Chan MY, Sun JL, Newby LK et al (2009) Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST elevation myocardial infarction. Circulation 119:3110–3117CrossRefPubMedGoogle Scholar
  18. 18.
    Becker RC (2002) Antithrombotic therapy after myocardial infarction. N Engl J Med 347:1019–1022CrossRefPubMedGoogle Scholar
  19. 19.
    Bassand JP, Hamm CW, Ardissino D et al (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598–1660CrossRefPubMedGoogle Scholar
  20. 20.
    Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 29:2909–2945CrossRefPubMedGoogle Scholar
  21. 21.
    Harrington RA, Becker RC, Cannon CP et al (2008) Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th edn). Chest 133:670S–707SCrossRefPubMedGoogle Scholar
  22. 22.
    Goodman SG, Menon V, Cannon CP et al (2008) Acute ST-segment elevation myocardial infarction: American College of Chest Physicians evidence-based clinical practice guidelines (8th edn). Chest 133:708S–775SCrossRefPubMedGoogle Scholar
  23. 23.
    Popovic JR, Kozak LJ (2000) National hospital discharge survey: annual summary, 1998. Vital Health Stat 13:1–194Google Scholar
  24. 24.
    Antman EM, Cohen M, Bernink PJ et al (2000) The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284:835–842CrossRefPubMedGoogle Scholar
  25. 25.
    Eagle KA, Lim MJ, Dabbous OH et al (2004) A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 291:2727–2733CrossRefPubMedGoogle Scholar
  26. 26.
    Boersma E, Pieper KS, Steyerberg EW et al (2000) Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT investigators. Circulation 101:2557–2567PubMedGoogle Scholar
  27. 27.
    Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502CrossRefPubMedGoogle Scholar
  28. 28.
    Carruthers KF, Dabbous OH, Flather MD et al (2005) Contemporary management of acute coronary syndromes: does the practice match the evidence? The global registry of acute coronary events (GRACE). Heart 91:290–298CrossRefPubMedGoogle Scholar
  29. 29.
    Roe MT, Parsons LS, Pollack CV Jr et al (2005) Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction. Arch Intern Med 165:1630–1636CrossRefPubMedGoogle Scholar
  30. 30.
    Mehta RH, Roe MT, Chen AY et al (2006) Recent trends in the care of patients with non-T-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med 166:2027–2034CrossRefPubMedGoogle Scholar
  31. 31.
    Yusuf S, Mehta SR, Chrolavicius S et al (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464–1476CrossRefPubMedGoogle Scholar
  32. 32.
    Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114:774–782CrossRefPubMedGoogle Scholar
  33. 33.
    Petersen JL, Mahaffey KW, Hasselblad V et al (2004) Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA 292:89–96CrossRefPubMedGoogle Scholar
  34. 34.
    Mehta SR, Steg PG, Granger CB et al (2005) Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra study in percutaneous coronary intervention: a randomized evaluation (ASPIRE) pilot trial. Circulation 111:1390–1397CrossRefPubMedGoogle Scholar
  35. 35.
    Ferguson JJ, Califf RM, Antman EM et al (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292:45–54CrossRefPubMedGoogle Scholar
  36. 36.
    White HD, Kleiman NS, Mahaffey KW et al (2006) Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the superior yield of the new strategy of enoxaparin, revascularization and glycoprotein IIb/IIIa inhibitors (SYNERGY) trial. Am Heart J 152:1042–1050CrossRefPubMedGoogle Scholar
  37. 37.
    DeWood MA, Spores J, Notske R et al (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897–902PubMedGoogle Scholar
  38. 38.
    Antman EM, Hand M, Armstrong PW et al (2008) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51:210–247CrossRefPubMedGoogle Scholar
  39. 39.
    Van de Werf F, Ardissino D, Betriu A et al (2003) Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society of cardiology. Eur Heart J 24:28–66CrossRefPubMedGoogle Scholar
  40. 40.
    de Bono DP, Simoons ML, Tijssen J et al (1992) Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 67:122–128CrossRefPubMedGoogle Scholar
  41. 41.
    Eisenberg PR (1992) Role of heparin in coronary thrombolysis. Chest 101:131S–139SPubMedGoogle Scholar
  42. 42.
    Collins R, Peto R, Baigent C, Sleight P (1997) Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 336:847–860CrossRefPubMedGoogle Scholar
  43. 43.
    Mahaffey KW, Granger CB, Collins R et al (1996) Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 77:551–556CrossRefPubMedGoogle Scholar
  44. 44.
    Yusuf S, Mehta SR, Xie C et al (2005) Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 293:427–435CrossRefPubMedGoogle Scholar
  45. 45.
    Antman EM, Morrow DA, McCabe CH et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:1477–1488CrossRefPubMedGoogle Scholar
  46. 46.
    Murphy SA, Gibson CM, Morrow DA et al (2007) Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 28:2077–2086CrossRefPubMedGoogle Scholar
  47. 47.
    Yusuf S, Mehta SR, Chrolavicius S et al (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519–1530CrossRefPubMedGoogle Scholar
  48. 48.
    Stone GW, Witzenbichler B, Guagliumi G et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218–2230CrossRefPubMedGoogle Scholar
  49. 49.
    Chen ZM, Jiang LX, Chen YP et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621CrossRefPubMedGoogle Scholar
  50. 50.
    Sabatine MS, Cannon CP, Gibson CM et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179–1189CrossRefPubMedGoogle Scholar
  51. 51.
    Smith P, Arnesen H, Holme I (1990) The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 323:147–152PubMedCrossRefGoogle Scholar
  52. 52.
    Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002) Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347:969–974CrossRefPubMedGoogle Scholar
  53. 53.
    Alexander JH, Becker RC, Bhatt DL et al (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. Circulation 119:2877–2885CrossRefPubMedGoogle Scholar
  54. 54.
    Mega JL, Braunwald E, Mohanavelus S et al (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS-ACS TIMI 46): a randomised, double-blind, phase II trial. Lancet 374:29–38CrossRefPubMedGoogle Scholar
  55. 55.
    Murphy SA, Antman EM, Wiviott SD et al (2008) Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 29:2473–2479CrossRefPubMedGoogle Scholar
  56. 56.
    Greenbaum AB, Grines CL, Bittl JA et al (2006) Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 151:689.e1–689.e10CrossRefGoogle Scholar
  57. 57.
    Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057CrossRefPubMedGoogle Scholar
  58. 58.
    Giugliano RP, White JA, Bode C et al (2009) Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360:1–15CrossRefGoogle Scholar
  59. 59.
    Mehta SR, Bassand JP, Chrolavicius S et al (2008) Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 156:1080–1088CrossRefPubMedGoogle Scholar
  60. 60.
    Double doses of clopidogrel better than standard dose for heart patients undergoing angioplasty, an international study find [press release]. Barcelona, Spain: ESC Congress 2009; August 30, 2009. http://www.escardio.org/about/press/press-releases/esc09-barcelona/Pages/esc-2009-Mehta-Current%20Oasis%207.aspx. Accessed 21 Oct 2009

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • S. Michael Gharacholou
    • 1
  • Renato D. Lopes
    • 1
  • Jeffrey B. Washam
    • 1
  • L. Kristin Newby
    • 1
  • Stefan K. James
    • 2
  • John H. Alexander
    • 1
    Email author
  1. 1.Duke Clinical Research InstituteDuke University Medical CenterDurhamUSA
  2. 2.Uppsala Clinical Research Centre, University HospitalUppsalaSweden

Personalised recommendations